Third-Party Tested ≥98% HPLC Purity — USA Shipped

Metabolic & Incretin Research Guide

Tesamorelin: Mechanism, Handling & Research Guide

Also known as: TH9507, stabilized GHRH analog

Key Facts

Tesamorelin is a metabolic & incretin research peptide (C223H370N72O69S, MW 5195.91 g/mol). Synthetic GHRH analogue studied for visceral fat reduction and metabolic health. It is supplied as a lyophilized powder for laboratory and in-vitro research use only — not for human consumption.

Classification Stabilized growth-hormone-releasing hormone analog
Molecular Formula C223H370N72O69S
Molecular Weight 5195.91 g/mol
CAS Number 901758-09-6
Research Half-Life Short (~26–38 minutes) but resistant to enzymatic degradation
Form Lyophilized powder
Research Category Metabolic & Incretin

What is Tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the 44-amino acid human GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus. It acts by binding to GHRH receptors on anterior pituitary somatotroph cells, stimulating pulsatile growth hormone (GH) release while preserving the natural hypothalamic-pituitary feedback axis. Beyond lipodystrophy research, studies published in Annals of Neurology (Baker et al., 2012) suggest tesamorelin may improve cognitive function in older adults with mild cognitive impairment by modulating IGF-1 levels in the central nervous system. Compared to direct GH use, tesamorelin preserves physiological GH pulsatility rather than creating supraphysiological sustained GH levels, which research indicates may reduce the risk of insulin resistance associated with exogenous GH. Additional preclinical work has explored its role in peripheral nerve regeneration models. The lyophilized powder should be stored at controlled room temperature (20-25C) or refrigerated; reconstitute with sterile water and use within 24 hours or refrigerate for up to 14 days. This peptide is studied by endocrinology research labs, HIV metabolism centers, and neuroscience institutions investigating GH-IGF-1 axis modulation.

Tesamorelin Research Applications

In published and preclinical research, Tesamorelin has been studied across the following areas:

  • HIV-associated lipodystrophy and visceral fat reduction
  • Peripheral nerve regeneration
  • Cognition and neurodegeneration models
  • Cardiovascular health through metabolic markers

Tesamorelin in Research: Study Context

Tesamorelin is a stabilized GHRH analog studied for its effect on the GH/IGF-1 axis and visceral adipose tissue. Research concentrations are model-specific; the lyophilized peptide is reconstituted with bacteriostatic water for laboratory use only.

How Tesamorelin Compares

Researchers frequently evaluate Tesamorelin alongside related compounds:

Tesamorelin — Frequently Asked Questions

Is Tesamorelin legal to buy for research?
Tesamorelin is sold in the United States as a research chemical for laboratory and in-vitro use only. It is not approved by the FDA for human use and is not sold for human consumption. Researchers are responsible for compliance with all applicable federal, state, and institutional regulations.
Does Tesamorelin come with a Certificate of Analysis?
Yes. Every batch of Tesamorelin from Elyte Peptides ships with a third-party Certificate of Analysis (COA) documenting identity and HPLC purity (≥98%), so research results can be traced to a verified lot.
What is Tesamorelin and how does it work?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification at the N-terminus. It binds to GHRH receptors on pituitary somatotroph cells, stimulating the pulsatile release of endogenous growth hormone. This mechanism has been studied for its downstream effects on IGF-1 levels, visceral adipose tissue metabolism, and hepatic lipid profiles.
What research has been done on Tesamorelin?
Tesamorelin has been studied in multiple clinical trials for HIV-associated lipodystrophy, where it received FDA approval (as Egrifta). Published research in the Journal of Clinical Endocrinology & Metabolism demonstrated significant reductions in visceral adipose tissue. Additional studies have explored its effects on peripheral nerve regeneration, mild cognitive impairment in aging populations, and non-alcoholic fatty liver disease biomarkers.
How does Tesamorelin compare to Sermorelin?
Both tesamorelin and sermorelin are GHRH analogues, but tesamorelin's trans-3-hexenoic acid modification provides greater resistance to enzymatic degradation, resulting in higher bioavailability and more potent GH release per exposure in research models. Sermorelin is a shorter fragment (amino acids 1-29 of GHRH), while tesamorelin includes the full 44-amino acid sequence with the N-terminal modification.

Research References

  1. Falutz J et al. Tesamorelin, a GHRH analogue, in patients with excess abdominal fat. NEJM 2007.
All research guides